Skip to main content

Sarepta Therapeutics (SRPT) - Get Sarepta Therapeutics, Inc. Report shares rose 6% Friday after the biotech company announced positive results from a gene therapy trial to treat a form of muscular dystrophy.

The company said the nine-month results showed improvements on functional measures seen in all three Limb-girdle muscular dystrophy Type 2E (LGMD2E) clinical trial participants. Limb-girdle muscular dystrophy is a term for a group of diseases that cause weakness and wasting of the muscles in the arms and legs.

Each patient in the trial received SRP-9003, an investigational gene therapy intended to "transduce skeletal and cardiac muscle with a gene that codes for the full-length, native beta-sarcoglycan protein, the lack of which is the sole cause of LGMD2E," the company said.

The stock was up $5 or 6% to $86.39.

TheStreet Recommends